These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18648813

  • 1. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
    Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA, Cancer and Leukemia Group B.
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):793-8. PubMed ID: 18648813
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, Wang M.
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E.
    J Clin Oncol; 2011 Mar 20; 29(9):1198-203. PubMed ID: 21300924
    [Abstract] [Full Text] [Related]

  • 7. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
    Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS.
    Ann Oncol; 2011 Jul 20; 22(7):1622-1627. PubMed ID: 21228334
    [Abstract] [Full Text] [Related]

  • 8. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
    Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B.
    J Clin Oncol; 2010 Nov 01; 28(31):4740-6. PubMed ID: 20837940
    [Abstract] [Full Text] [Related]

  • 9. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF.
    Ann Oncol; 2006 May 01; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
    Ribrag V, Koscielny S, Vantelon JM, Fermé C, Rideller K, Carde P, Bourhis JH, Munck JN.
    Leuk Lymphoma; 2003 Sep 01; 44(9):1529-33. PubMed ID: 14565655
    [Abstract] [Full Text] [Related]

  • 11. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM.
    Leuk Lymphoma; 2007 Feb 01; 48(2):374-80. PubMed ID: 17325899
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
    Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH.
    J Clin Oncol; 2014 Jan 01; 32(1):44-50. PubMed ID: 24043741
    [Abstract] [Full Text] [Related]

  • 13. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM.
    J Clin Oncol; 2008 Oct 20; 26(30):4952-7. PubMed ID: 18606983
    [Abstract] [Full Text] [Related]

  • 14. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, Chen T, Klein C, Hagner PR, Nikolova Z, Ribrag V.
    Lancet Haematol; 2020 Sep 20; 7(9):e649-e659. PubMed ID: 32758434
    [Abstract] [Full Text] [Related]

  • 15. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
    Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE.
    Leukemia; 2011 Dec 20; 25(12):1877-81. PubMed ID: 21720383
    [Abstract] [Full Text] [Related]

  • 16. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
    Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD.
    J Clin Oncol; 1992 Mar 20; 10(3):371-7. PubMed ID: 1346801
    [Abstract] [Full Text] [Related]

  • 17. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.
    Lancet Oncol; 2017 Feb 20; 18(2):230-240. PubMed ID: 28089635
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 20; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 19. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M, Kröger N, Kroschinsky F, Birkmann J, Hänel A, Herbst R, Naumann R, Friedrichsen K, Ehninger G, Zander AR, Fiedler F.
    J Cancer Res Clin Oncol; 2001 Apr 20; 127(6):387-95. PubMed ID: 11414199
    [Abstract] [Full Text] [Related]

  • 20. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA.
    Lancet Oncol; 2018 Apr 20; 19(4):486-496. PubMed ID: 29475723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.